Drugs Made In America Acquisition II (DMII)
Blank-check company seeking a pharmaceutical-focused business combination.
$10.17
At close+0.02 (+0.15%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions68 holders · as of Mar 31, 2026 | 68.96% | 43.93M shares | |
| Insiders4 holders · as of Oct 17, 2025 | 0.63% | 400.0K shares | |
| Otherremainder | 30.41% | 19.37M shares |
63.70M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
68 holders · 43.93M shares · 19 new positions · 30 increased · 15 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Magnetar Financial LLC | 2.70M | 4.24% | 0 | May 13, 2026 |
| Mmcap International Inc. SPC | 2.70M | 4.24% | +2.70Mnew | May 15, 2026 |
| Karpus Management, Inc. | 2.60M | 4.08% | +1.45M | May 14, 2026 |
| Glazer Capital, LLC | 2.35M | 3.69% | −138 | May 14, 2026 |
| Healthcare of Ontario Pension Plan Trust Fund | 2.00M | 3.14% | +2.00Mnew | May 14, 2026 |
| Millennium Management LLC | 1.98M | 3.10% | +476.4K | May 15, 2026 |
| Hudson Bay Capital Management LP | 1.97M | 3.09% | 0 | May 13, 2026 |
| Wolverine Asset Management LLC | 1.80M | 2.82% | +732.5K | May 4, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Drugs Made In America Acquisition II LLCincl. Lynn Stockwell | 10.20% | 6.71M | 13D | Oct 2, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 26, 2025 | Drugs Made In America Acquisition II LLC10 percent owner | Purchase · 2 lots | 1,400,000 | 15,775,000 | |
| Sep 26, 2025 | Drugs Made In America Acquisition II LLC10 percent owner | Sale | 7,966,667 | $1.50 | 6,708,333 |
| Sep 26, 2025 | Lynn Stockwelldirector, 10 percent owner, officer: CEO and Exe. Chair of Board | Purchase · 2 lots | 1,400,000 | 15,775,000 | |
| Sep 26, 2025 | Lynn Stockwelldirector, 10 percent owner, officer: CEO and Exe. Chair of Board | Sale | 7,966,667 | $1.50 | 6,708,333 |
CongressHouse and Senate disclosures
Not reported.